Effect of Food on the Pharmacokinetics of Fluoxetine in Healthy Male Adult Volunteers(Conference Paper )#
DOI:
https://doi.org/10.31351/vol31issSuppl.pp153-161Keywords:
Fluoxetine, Pharmacokinetics, Food effect, Arabic volunteers.Abstract
Fluoxetine (FX) is an antidepressant drug administered only orally in humans. Despite the wide use of FX, until now, there is only limited literature concerning the pharmacokinetics (PK) of FX and the effect of food on its PK. Thus, the objective of this investigation was to study the PK of FX in Arabic healthy male adult volunteers under fasting and fed conditions. In the fasting study, FX 20 mg capsules (Prozac®, Eli Lilly, Canada) were administered to 41 volunteers after overnight fasting of 12 hours, followed by blood sampling from each volunteer immediately before dosing (zero time) and then at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 36, 48, 60, 72, 96, 120, and eventually at 144 hours after FX dosing. The fed study was conducted after 90 days wash-out period following the completion of the fasting study. The same subjects who received FX in the fasting study were administered the drug directly after a fatty breakfast (fed study), followed by blood sampling intervals similar to the schedule mentioned above for the fasting study. The current investigation demonstrated no statistical differences in the FX pharmacokinetic parameters Cmax, AUC0–t, AUC0–∞, Kel, T1/2, MRT, Cl/F, and Vd/F after fasting compared to the fed conditions, whereas there was statistically significant elongation in the Tmax values after food intake. Therefore, this study concludes the absence of food effect on the PK of FX (except Tmax) in the Arabic population and confirms the method of administration mentioned in the product information but also concludes high interindividual variation in FX exposure (AUC), which suggest that therapeutic drug monitoring (TDM) might be advisable when feasible.
References
Kabinoff GS, Plewes JM, Wilson MG. Weekly formulation of fluoxetine for newly treated patients with depression. Clin Drug Invest. 2002;22(6):403-405.
Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive compulsive disorder: comparative studies. J Clin Psychiatry.1997;58(Suppl 12):18-22.
Malavika D, Sweilem B Al R, Lucy D, Jacques T, Veronique M. Assessing the mechanism of fluoxetine-mediated CYP2D6 inhibition. Pharmaceutics. 2021;13(148):1-10.
Liu Z-Q, Cheng Z-N, Huang S-L, et al. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol. 2001;52(1):96-99.
Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin. Pharmacokinet. 1994; 26(3):201-214.
Darshan KP, Tapash KG. Feasibility of transdermal delivery of fluoxetine. AAPS PharmSciTech. 2005;30,6:(2):E144-9.
Emoke-Margit R, Paula A, Nicoleta T, Robert AV, Magdalena B, Anamaria T, Adriana C. Development and evaluation of fluoxetine fast dissolving films. an alternative for noncompliance in pediatric patients. Processes. 2021;9(778):2-14.
Al-Tamimi DJ, Hussein AA. Formulation and characterization of self-microemulsifying drug delivery system of tacrolimus. Iraqi J Pharm Sci. 2021;30(1):91-100.
Al-Tamimi DJ, Hussein AA. Preparation and in-vitro characterization of tacrolimus as a solid self-microemulsion. IJDDT. 2021;11(1):70-78.
Alani ME, Al-Tamimi DJ, Al-Mahroos MI, Ammoo1 AM, Al-Tamim MJ, Ibraheem JJ. Bioequivalence study of a newly developed azithromycin suspension versus Zithromax® following a single dose to healthy fasting adult subjects. IJDD. 2021;11(1):159-165.
Jabbar EG, Al-Tamimi DJ, Al-Mahroos MI, Al-Tamimi ZJ, Ibraheem JJ. Pharmacokinetics and bioequivalence study of two formulations of cefixime suspension. J Adv Pharm Edu Res. 2021;11(1):170-177.
Afaq M. Ammoo, Duaa J. Al-Tamimi, Mustafa I. Al-Mahroos, Mariam J. Al-Tamimi, Jaafar J. Ibraheem. Bioequivalence and pharmacokinetic comparison of two levofloxacin oral formulations in arabic healthy men. IJDDT. 2021;11(3):762-770.
Duaa Jaafar Jaber Al-Tamimi, Mustafa Ihssan Abbas Al-Mahroos, Mariam Jaafar Jaber Al-Tamimi, Jaafar Jaber Ibraheem. Pharmacokinetic comparison and bioequivalence evaluation between a newly formulated generic and the brand cefuroxime axetil tablets in healthy male adult fasting subjects. Research Journal of Pharmacy and Technology (RJPT).2022; 15 (5) :2184-2
Al-Mahroos MI, Al-Tamimi DJ, Al-Tamimi ZJ, Ibraheem JJ. Clinical pharmacokinetics and bioavailability study between generic and branded fluconazole capsules. J Adv Pharm Edu Res. 2021;11(1):161-169.
Afaq Mahde Ammoo, Duaa Jaafar Jaber Al-Tamimi, Mustafa Ihssan Abbas Al-Mahroos, Mariam Jaafar Jaber Al-Tamimi, Jaafar Jaber Ibraheem. Pharmacokinetics of fluconazole tablets administered to healthy subjects. J Adv Pharm Edu Res. 2021;11(2):92-99.
Abass HM, Al-Tamimi KF, Al-Tamimi DJ, Ibraheem JJ. Correlation between cyclosporine blood levels and area under blood concentration time curve in Iraqi bone marrow transplant patients treated with Neoral® oral solution. Sci Pharm. 2020;88(8):1-12.
Al-Tamimi DJ., Alani ME., Ammoo AM., Ibraheem JJ. Linear pharmacokinetics of doxazosin in healthy subjects. Int J Res Pharm. Sci.2020;11(1):1031-1039.
Al-Tamimi DJ, Ammoo AM, Alani ME, Ibraheem JJ. Pharmacokinetics and dose proportionality of betahistine in healthy individuals. Sci Pharm. 2020;88(13):1-8.
Al-Tamimi DJ, Maraie NK, Arafat T. Comparative bioavailability (bioequivalence) study for fixed dose combination tablet containing amlodipine, valsartan and hydrochlorothiazide using a newly developed HPLC-MS/MS method. Int J Pharm Sci. 2016;8(7):296-305.
International council for harmonization of technical requirements for pharmaceuticals for human use (ICH), ICH harmonized guidance: guidance for good clinical practice E6(R2), November 2016.
E6(R2) Good clinical practice: integrated addendum to ICH E6(R1), guidance for industry, U.S. Department of health and human services, food and drug administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), March 2018.
WMA Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects, 64th WMA General Assembly, Fortaleza, Brazil. 2013.
Yarra DP, Yashpal SC, Hardik C, Tulsankar SL, Veenu B, Sanjeev K, Sandeep G, Rabi SB Ghatak. Sensitive and high-throughput bioanalysis of fluoxetine and nor-fluoxetine in rabbit and human plasma using SPE-LC-MS/MS. Anal Methods. 2015;7(10):4340-4347.
Guidance for Industry: US department for health & human services: bioanalytical method validation for human studies, FDA, Centre for Drug Evaluation and Research (CDER), 2001.
Guidance for Industry: US Department for health & human services: Bioanalytical method validation for human studies, FDA, Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), 2018.
Leon S., Andrew BCY, Murray D. Shargel and Yu’s Applied Biopharmaceutics & Pharmacokinetics, 8th ed. McGraw-Hill Education/Medical: New York, NY, USA. 2021.
Hartmut D, Stephan S. Rowland and Tozer’s Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 5th ed. LWW: Philadelphia, PA, USA. 2019.
Keller T, Cambon N, Genevray M, Crivelli F, Crivelli M, Dal BL, Mazzucchelli P, Ismaili S, Marzo A. Bioequivalence study of fluoxetine hydrochloride in healthy volunteers.Arzneimittelforschung. 2005;55(9):491-497.
Zaid AN , Bowirrat A , Kort JJ, Oscar-Berman M. Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers . Int J Clin Pharmacol Ther.2006;44(11):593-602.
Naji MN, Nasir I, Muntaser B, Mohammed B, Isra A, Mahmood AS, Ruwayda D, Qumaruzaman. Bioequivalence evaluation of two brands of fluoxetine 20 mg capsules (Flutin and Prozac) in healthy human volunteers. Biopharm. Drug Dispos. 2007;26:243–247.
Paulo M, Gilberto A, Adrián L , Amílcar F. Therapeutic drug monitoring of fluoxetine, norfluoxetine and paroxetine: A new tool based on microextraction by packed sorbent coupled to liquid chromatography. J Anal Toxicol. 2017;41(7):631–638.
Milan G, Ivana K, Romana U. Therapeutic monitoring of psychoactive drugs - antidepressants: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):35-43.
Concetta C, Chiara F, Stefano P, Antonio D, Edoardo S, Diana De R, Alessandro S. Pharmacogenetics of antidepressants. Front Pharmacol. 2011;16,(2):6.
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195-235.
Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacology & Therapeutics. 2009;124(1):57–73.
Sharon R-L, Chad E B, Zoë A H, Xavier K, Somana J R, Jessica E M, Zia R, Robert H R, Lee E S. Differentiating antidepressants of the future: efficacy and safety Pharmacol Ther. 2007;113(1):134-153.
Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry. 2006;39(4):121-127.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.
